BIOMAT Database Logo BIOMAT Database Logo

Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. 1989

J L Abbruzzese, and B Levin, and J A Ajani, and J S Faintuch, and S Saks, and Y Z Patt, and C Edwards, and K Ende, and J U Gutterman
Department of Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030.

Recombinant human gamma-interferon and recombinant human tumor necrosis factor are two representatives of a new class of antineoplastic agents. In vitro studies have suggested synergistic cytotoxic activities when the agents are combined. We report a phase I study of these two agents when administered daily for 5 consecutive days every 2 weeks in patients with advanced gastrointestinal cancers. Toxicity resulting from these agents was significant with hyperbilirubinemia representing the dose-limiting toxicity. Significant, although transient, myelosuppression was also observed. The maximal tolerated doses were 150 micrograms/m2/day for 5 days for each agent. Suggestive antineoplastic activity in biliary and pancreatic cancer was observed. Phase II trials of this combination are currently in progress.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005770 Gastrointestinal Neoplasms Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL. Gastrointestinal Cancer,Cancer of Gastrointestinal Tract,Cancer of the Gastrointestinal Tract,Neoplasms, Gastrointestinal,Cancer, Gastrointestinal,Cancers, Gastrointestinal,Gastrointestinal Cancers,Gastrointestinal Neoplasm,Gastrointestinal Tract Cancer,Gastrointestinal Tract Cancers,Neoplasm, Gastrointestinal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J L Abbruzzese, and B Levin, and J A Ajani, and J S Faintuch, and S Saks, and Y Z Patt, and C Edwards, and K Ende, and J U Gutterman
A phase II combination trial with recombinant human tumor necrosis factor and gamma interferon in patients with colorectal cancer.
April 1991, Klinische Wochenschrift,
J L Abbruzzese, and B Levin, and J A Ajani, and J S Faintuch, and S Saks, and Y Z Patt, and C Edwards, and K Ende, and J U Gutterman
Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma.
October 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy,
J L Abbruzzese, and B Levin, and J A Ajani, and J S Faintuch, and S Saks, and Y Z Patt, and C Edwards, and K Ende, and J U Gutterman
Phase I study of a combination of recombinant tumor necrosis factor-alpha and recombinant interferon-gamma in cancer patients.
August 1989, Journal of interferon research,
J L Abbruzzese, and B Levin, and J A Ajani, and J S Faintuch, and S Saks, and Y Z Patt, and C Edwards, and K Ende, and J U Gutterman
A phase I trial with recombinant interferon gamma (Roussel UCLAF) in advanced cancer patients.
January 1990, Cancer immunology, immunotherapy : CII,
J L Abbruzzese, and B Levin, and J A Ajani, and J S Faintuch, and S Saks, and Y Z Patt, and C Edwards, and K Ende, and J U Gutterman
A phase I trial of recombinant human gamma interferon (IFN-gamma 4A) in patients with advanced malignancy.
June 1988, Journal of biological response modifiers,
J L Abbruzzese, and B Levin, and J A Ajani, and J S Faintuch, and S Saks, and Y Z Patt, and C Edwards, and K Ende, and J U Gutterman
Phase I trial of recombinant interferon gamma in cancer patients.
February 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J L Abbruzzese, and B Levin, and J A Ajani, and J S Faintuch, and S Saks, and Y Z Patt, and C Edwards, and K Ende, and J U Gutterman
Granulocytopenia in cancer patients treated in a phase I trial with recombinant human tumor necrosis factor.
April 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy,
J L Abbruzzese, and B Levin, and J A Ajani, and J S Faintuch, and S Saks, and Y Z Patt, and C Edwards, and K Ende, and J U Gutterman
A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo.
October 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J L Abbruzzese, and B Levin, and J A Ajani, and J S Faintuch, and S Saks, and Y Z Patt, and C Edwards, and K Ende, and J U Gutterman
Phase I clinical trial of recombinant human tumor necrosis factor.
January 1987, Cancer chemotherapy and pharmacology,
J L Abbruzzese, and B Levin, and J A Ajani, and J S Faintuch, and S Saks, and Y Z Patt, and C Edwards, and K Ende, and J U Gutterman
A phase I/II study of recombinant tumor necrosis factor and recombinant interferon gamma in patients with AIDS-related complex.
January 1989, Biotechnology therapeutics,
Copied contents to your clipboard!